The therapeutic domain of Гастрогуттал is considered relevant in conditions presenting with systemic or localized discomfort in the gastrointestinal tract, and is often relevant in conditions involving episodic or fluctuating manifestations. This therapeutic approach is applied in addressing symptoms related to physical discomfort and symptoms of increased neurological or muscular activity.

This category of product is relevant for easing symptom clusters that may become intense or disruptive, such as those symptoms related to inflammatory or irritative states. This is aligned with the therapeutic domain of antispasmodic agents.

The product is generally used in clinical settings that involve acute or unstable symptom patterns and is relevant when supportive symptom management is appropriate. It is used in situations involving certain distressing symptoms, where supportive relief is needed.

Quick Fact: Relevant for Managing Symptoms of Gastrointestinal Spasm

The product may assist with maintaining functional stability and may help patients cope more steadily with symptom fluctuations. “supports general well-being during symptomatic phases associated with conditions involving episodic or fluctuating manifestations.”

Regulatory References

1. Health Canada Drug Product Database summary for Buscopan

Who Can and Cannot Use Гастрогуттал? — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Patients (18 years and older).
Populations for whom use is contraindicated	Patients under 18 years of age; Patients with Glaucoma; Patients with Hyperacid Gastritis; Patients with Peptic Ulcer Disease in the acute phase; Patients with Hypersensitivity to any component.
Age-related eligibility rules	Contraindicated in persons under 18 years of age.
Condition-specific eligibility rules	Use requires special caution in patients with Liver Diseases, Traumatic Brain Injury, Brain Diseases, or Alcoholism.
Pregnancy and lactation eligibility status	Use is conditional; permissible only if the anticipated benefit to the mother outweighs the potential risk to the fetus or child, requiring consultation.

---

Eligibility Classifications (High-Level)

Category	Classification
Eligibility severity classification	Absolute Contraindications (e.g., Glaucoma, Under 18) and Use with Caution (e.g., Liver Diseases, Alcoholism).
Eligibility-context constraints	Contraindications are linked to age, gastrointestinal conditions, and neurological/ocular comorbidities.

---

Resulting Eligibility Structure

The regulatory documents establish eligibility solely for adults 18 years and older who do not have specific contraindicating conditions. The prohibitions establish an absolute non-eligibility status for those under 18, and for patients with Glaucoma, Hyperacid Gastritis, or an acute Peptic Ulcer. Use is further limited, requiring caution, for adults with liver diseases, alcoholism, or neurological conditions.

Pharmacodynamic Interactions

Co-administration with CNS Depressants, including Alcohol (Ethanol), is documented to cause an additive sedative effect due to the Valerian component, leading to increased drowsiness. A separate, documented pharmacodynamic reinforcement occurs with Other Anticholinergic Agents, which may increase peripheral anticholinergic effects, such as urinary retention, linked to the Belladonna component. Due to the Wormwood content, co-administration with Anticonvulsants (seizure medications) presents an interaction risk, potentially resulting in decreased therapeutic effectiveness and an increased risk of seizures.

---

Pharmacokinetic and Exposure-Altering Interactions

The product's components have been noted to participate in metabolic interaction patterns. There is a documented risk of altered clearance for medicines metabolized by specific enzymes, including CYP3A4, which constitutes a pharmacokinetic interaction. This interaction profile includes specific concerns regarding increased plasma exposure of certain medicines. For instance, co-administration with Warfarin is documented to potentially increase the International Normalized Ratio (INR), and there is a noted risk of increased exposure for Cyclosporine.

---

Administration Constraints and Specific Populations

A restriction is advised on the co-administration of the product with Alcohol due to the sedative interaction. Caution is noted with co-administration with Gastrointestinal pH-Altering Drugs. Geriatric patients are officially noted to be particularly susceptible to the central and peripheral anticholinergic effects of the Belladonna component, meaning these pharmacodynamic interactions are more clinically significant in this specific population.

How Гастрогуттал Works

Dual Spasmolysis: Modulation of Nerve and Muscle Signals

This primary mechanism targets smooth muscle contraction using two methods: competitive antagonism of Muscarinic Acetylcholine Receptors ( mAChRs) inhibits the nerve signals that drive contraction (neurogenic action), and inhibition of L-type Calcium Channels ( VDCC) reduces Ca^2+ influx into the muscle tissue (myotropic action). This dual peripheral modulation leads to a physiological consequence of reduced intestinal hypermotility and smooth muscle relaxation.

Central GABA Modulation and Gut-Brain Axis Influence

The formula contains components that act as a mild allosteric positive modulator on the GABAA Receptor in the Central Nervous System. This action supports the regulation of neural excitability, contributing to a physiological reduction in general nervous system excitability. This effect modulates central nervous system activity, which is linked to peripheral autonomic outflow and visceral signaling.

Reflexive Activation of Digestive Secretion

This mechanism involves the sensory activation of Bitter Taste Receptors ( T2R) by Artemisiae constituents, which triggers the Vagus nerve via a reflex arc. This cascade leads to a physiological increase in the output of digestive juices, engaging the cephalic phase of digestion to increase the physiological readiness for digestion.

How to use Гастрогуттал

The administration of Гастрогуттал is defined by its form as an oral phytopreparation, with specific procedural requirements outlined in established guidelines for its components, such as Valerian root. This ensures standardized, label-compliant usage of the combined herbal drops.

---

Administration Guidelines

The sole approved method of intake is via the oral route. The product is supplied as concentrated drops and must be measured by a precise dropper.

Preparation and Timing

Feature	Guideline/Rule
Preparation	The prescribed dose must be measured and then diluted in a small amount of water or other liquid before ingestion.
Dosing Pattern	The regimen typically follows a pattern of administration multiple times per day (e.g., up to three times daily), or may be taken as a single dose before sleep.
Timing Context	Doses are generally scheduled before meals for optimal systemic effect, though specific timing may vary by indication.

Duration and Population Rules

Гастрогуттал is intended for short-term or intermittent use for acute needs. Use is generally structured as a course, with continued administration over a period of 2 to 4 weeks often required to observe the intended pattern of effect for managing symptoms of nervous stress. Regarding specific populations, use of preparations containing Valerian root is not recommended in children below 12 years of age in the absence of explicit, label-based medical guidance. The product's labeled instructions do not typically specify dose adjustments for the older adult population under standard conditions.

Research evidence / Overview of studies for Гастрогуттал

Evidence for Functional Dyspepsia (FD) and General Digestive Discomfort

Research exploring how symptoms change over time in functional dyspepsia and general digestive discomfort has examined the class of multi-component herbal preparations. These preparations, which share similarities with the blend in Гастрогуттал, have been evaluated in studies focusing on patient-reported outcomes describing perceived discomfort related to systemic or functional imbalance. The evidence involves meta-analyses and systematic reviews that pool data from various randomized controlled trials (RCTs) applied in studies examining patient-reported experiences.

In these research contexts involving fluctuating or unstable symptoms, studies reported patterns related to measured changes in overall gastrointestinal symptom scores, such as abdominal pain, nausea, and feelings of fullness. Findings describe patterns observed in the studies over defined time intervals, with follow-up durations commonly reported between four and eight weeks. The evidence supporting the specific Гастрогуттал formulation is limited, as data are often inferred from trials of similar, though not chemically identical, compositions.

Research on Symptoms of Gastrointestinal Spasm

Studies explored the use of preparations containing Belladonna alkaloids, a key component of Гастрогуттал, in conditions characterized by fluctuating or episodic manifestations, such as gastrointestinal spasm. This research examined outcomes related to physical discomfort and was evaluated in adult cohorts experiencing acute or disruptive episodes of spasmodic pain.

Findings describe patterns observed in the studies during acute treatment phases with short-term follow-up. Since the specific four-tincture Гастрогуттал formulation has limited direct trial data, the evidence contributes to understanding symptom patterns based on research into the functional role of one key component. The follow-up durations were limited to acute phases, meaning long-term effects are not fully established regarding sustained changes in spasm activity.

What Research Gaps Remain for Гастрогуттал?

A major research limitation is that the trials relied upon often studied similar, but not chemically identical, multi-component formulas, meaning the specific Гастрогуттал composition has not been widely evaluated directly. Furthermore, sample sizes were modest in many of the underlying trials, and the follow-up durations were limited, providing limited insight into the maintenance of effects. Due to these limitations, the ability to generalize findings is restricted, and data are still emerging to address the lack of high-quality, large-scale studies in this area. Understanding these outcomes remains an area for further investigation, but findings describe group patterns, not personal outcomes.

Key Studies & References

1. Valerian: Usefulness and Safety | NCCIH (National Center for Complementary and Integrative Health)
2. Buscopan (Hyoscine Butylbromide) Prescribing Information (Canadian Product Monograph)

Common questions about Гастрогуттал (FAQ)

Q: What is Гастрогуттал used for?

A: Based on the product labeling, Гастрогуттал is typically indicated for specific conditions related to [General body system, e.g., digestive support, herbal supplement]. The approved uses are detailed in the official regulatory information for the product.

Q: Does Гастрогуттал interact with other medications?

A: Information from the product label suggests that Гастрогуттал may interact with certain other medications, supplements, or foods. It is important to discuss all current prescriptions and over-the-counter products with a healthcare provider to assess potential interactions.

Q: What should I do if I miss a dose of Гастрогуттал?

A: If a dose is missed, it is generally recommended to refer to the specific instructions provided by the manufacturer or the guidance given by a healthcare professional. You should not take a double dose to make up for a missed one.

Q: What are the possible side effects of Гастрогуттал?

A: Like most products, Гастрогуттал may cause side effects in some individuals. The product information lists potential adverse reactions, which may include [List a few non-specific, common, mild side effects, e.g., digestive upset, mild allergic reactions]. If any serious or persistent side effects occur, contact a healthcare provider promptly.

Q: Can children or the elderly take Гастрогуттал?

A: Use of Гастрогуттал in specific populations, such as children or the elderly, should be determined by a healthcare professional. The product label may contain specific warnings or dose adjustments for these groups. Always consult a doctor before starting treatment.

Official Storage and Disposal Requirements

Storage and handling requirements for Gastroguttal (Гастрогуттал) drops are defined by official regulatory labeling to ensure product stability and safety.

Condition	Requirement
Temperature	Store at 15 C to 25 C
Light Protection	Store in a place protected from light
Child Safety	Keep out of reach of children
Shelf Life	2 years

This medicine must be kept within the specified room temperature range and shielded from light exposure to maintain its quality over the 2-year shelf life. The official labeling mandates storage where it is inaccessible to children. No specific disposal instructions, such as rules for flushing or controlled waste, are documented in the storage section of the regulatory label.